Renalytix Plc (RNLX)
Total Valuation
Renalytix has a market cap or net worth of $54.56 million. The enterprise value is $57.43 million.
Market Cap | 54.56M |
Enterprise Value | 57.43M |
Important Dates
The last earnings date was Wednesday, February 14, 2024, after market close.
Earnings Date | Feb 14, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Renalytix has 49.97 million shares outstanding.
Shares Outstanding | 49.97M |
Owned by Insiders (%) | 4.66% |
Owned by Institutions (%) | 8.64% |
Float | n/a |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 22.64 |
Forward PS | n/a |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 23.83 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.59
Current Ratio | 0.59 |
Quick Ratio | 0.50 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -1,071.90% and return on invested capital (ROIC) is -7,269.13%.
Return on Equity (ROE) | -1,071.90% |
Return on Assets (ROA) | -165.30% |
Return on Capital (ROIC) | -7,269.13% |
Revenue Per Employee | $23,627 |
Profits Per Employee | -$410,284 |
Employee Count | 102 |
Asset Turnover | 0.10 |
Inventory Turnover | n/a |
Taxes
In the past 12 months, Renalytix has paid $7,000 in taxes.
Income Tax | 7,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.37% in the last 52 weeks. The beta is 1.92, so Renalytix's price volatility has been higher than the market average.
Beta (1Y) | 1.92 |
52-Week Price Change | -60.37% |
50-Day Moving Average | 0.75 |
200-Day Moving Average | 1.47 |
Relative Strength Index (RSI) | 48.05 |
Average Volume (30 Days) | 1,993,968 |
Short Selling Information
Short Interest | 894,619 |
Short Previous Month | 500,571 |
Short % of Shares Out | 1.52% |
Short % of Float | n/a |
Short Ratio (days to cover) | 0.43 |
Income Statement
In the last 12 months, Renalytix had revenue of $2.41 million and -$41.85 million in losses. Loss per share was -$0.90.
Revenue | 2.41M |
Gross Profit | 152,000 |
Operating Income | -38.38M |
Pretax Income | -41.84M |
Net Income | -41.85M |
EBITDA | -41.25M |
EBIT | -41.84M |
Loss Per Share | -$0.90 |
Balance Sheet
The company has $5.62 million in cash and $8.48 million in debt, giving a net cash position of -$2.87 million or -$0.06 per share.
Cash & Cash Equivalents | 5.62M |
Total Debt | 8.48M |
Net Cash | -2.87M |
Net Cash Per Share | -$0.06 |
Equity / Book Value | -7.96M |
Book Value Per Share | -0.16 |
Working Capital | -5.67M |
Cash Flow
Operating Cash Flow | -36.16M |
Capital Expenditures | n/a |
Free Cash Flow | -36.16M |
FCF Per Share | -$0.74 |
Margins
Gross margin is 6.31%, with operating and profit margins of -1,592.57% and -1,736.47%.
Gross Margin | 6.31% |
Operating Margin | -1,592.57% |
Pretax Margin | -1,736.18% |
Profit Margin | -1,736.47% |
EBITDA Margin | -1,711.45% |
EBIT Margin | -1,736.18% |
FCF Margin | -1,500.29% |
Dividends & Yields
Renalytix does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -29.88% |
Shareholder Yield | -29.88% |
Earnings Yield | -76.70% |
FCF Yield | -66.27% |
Analyst Forecast
The average price target for Renalytix is $4.25, which is 394.19% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $4.25 |
Price Target Difference | 394.19% |
Analyst Consensus | Strong Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Renalytix has an Altman Z-Score of -35.39 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -35.39 |
Piotroski F-Score | 3 |